EP2167110A4 - Nasal verabreichte impfstoffe mit multi-screened nalt-targeting und phagozytischen polypeptid-transportsequenzen - Google Patents

Nasal verabreichte impfstoffe mit multi-screened nalt-targeting und phagozytischen polypeptid-transportsequenzen

Info

Publication number
EP2167110A4
EP2167110A4 EP08756895A EP08756895A EP2167110A4 EP 2167110 A4 EP2167110 A4 EP 2167110A4 EP 08756895 A EP08756895 A EP 08756895A EP 08756895 A EP08756895 A EP 08756895A EP 2167110 A4 EP2167110 A4 EP 2167110A4
Authority
EP
European Patent Office
Prior art keywords
nalt
phagocytic
nasal
targeting
screened
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08756895A
Other languages
English (en)
French (fr)
Other versions
EP2167110A1 (de
Inventor
Ian Andrew Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2167110A1 publication Critical patent/EP2167110A1/de
Publication of EP2167110A4 publication Critical patent/EP2167110A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/14042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/14045—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP08756895A 2007-06-08 2008-06-06 Nasal verabreichte impfstoffe mit multi-screened nalt-targeting und phagozytischen polypeptid-transportsequenzen Withdrawn EP2167110A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007202629A AU2007202629A1 (en) 2007-06-08 2007-06-08 Nasal-administered vaccines
PCT/AU2008/000811 WO2008148164A1 (en) 2007-06-08 2008-06-06 Nasal-administered vaccines using multi-screened nalt-targeting and phagocytic polypeptide transport sequences

Publications (2)

Publication Number Publication Date
EP2167110A1 EP2167110A1 (de) 2010-03-31
EP2167110A4 true EP2167110A4 (de) 2012-02-29

Family

ID=40093083

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08756895A Withdrawn EP2167110A4 (de) 2007-06-08 2008-06-06 Nasal verabreichte impfstoffe mit multi-screened nalt-targeting und phagozytischen polypeptid-transportsequenzen

Country Status (4)

Country Link
EP (1) EP2167110A4 (de)
AU (1) AU2007202629A1 (de)
CA (1) CA2727126A1 (de)
WO (1) WO2008148164A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014085297A1 (en) * 2012-11-27 2014-06-05 Colorado State University Research Foundation Multifunctional bacteriophage for delivery of therapeutic agents and imaging reagents
EP4125975A4 (de) * 2020-03-27 2024-05-01 Atossa Therapeutics, Inc. Verfahren zum behandeln oder vorbeugen einer virusinfektion unter verwendung von bakteriophagen
CN113604481B (zh) * 2021-07-07 2023-05-02 江苏农牧科技职业学院 一种t7噬菌体识别的锚定序列、dna疫苗重组质粒及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072015A2 (en) * 2001-03-12 2002-09-19 Montana State University-Bozeman M cell directed vaccines
US20030211476A1 (en) * 2001-04-04 2003-11-13 O'mahony Daniel Genetic analysis of peyer's patches and M cells and methods and compositions targeting peyer's patches and M cell receptors
US20080233049A1 (en) * 2004-06-23 2008-09-25 Ian Andrew Ferguson Agents And Methods For Early Diagnosis And Monitoring Of Alzheimer's Disease And Other Neurological Disorders
WO2006078567A2 (en) * 2005-01-21 2006-07-27 Montana State University Vaccines and mucosal targeting ligands to facilitate vaccine delivery

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUKREYEV ET AL: "Nonsegmented Negative-Strand Viruses as Vaccine Vectors", JOURNAL OF VIROLOGY,, vol. 80, no. 21, 1 November 2006 (2006-11-01), pages 10293 - 10306, XP008109018, DOI: 10.1128/JVI.00919-06 *
DELMASTRO P ET AL: "Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration", VACCINE, ELSEVIER LTD, GB, vol. 15, no. 11, 1 August 1997 (1997-08-01), pages 1276 - 1285, XP004086601, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(97)00072-8 *
See also references of WO2008148164A1 *

Also Published As

Publication number Publication date
WO2008148164A1 (en) 2008-12-11
CA2727126A1 (en) 2008-12-11
EP2167110A1 (de) 2010-03-31
AU2007202629A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
IL219048A (en) Peptide compounds derived from urcl10
IL203899A (en) Foxm1-derived peptide compounds
IL220752A0 (en) Tem8 peptides and vaccines comprising the same
IL209967A0 (en) Cdca1 epitope peptides and vaccines containing the same
HK1157204A1 (zh) 表位肽及包含它們的疫苗
IL214435A0 (en) Foxm1 peptides and vaccines containing the same
IL229926A (en) 3neil peptides and vaccines containing them
IL199622A0 (en) Foxp3 peptide vaccine
IL216211A0 (en) Cdc45l peptides and vaccines including the same
EP2430039A4 (de) Ttk-peptide und diese enthaltende impfstoffe
IL213318A0 (en) C1orf59 peptides and vaccines including the same
IL214453A0 (en) Vangli peptides and vaccines including the same
EP2167110A4 (de) Nasal verabreichte impfstoffe mit multi-screened nalt-targeting und phagozytischen polypeptid-transportsequenzen
GB0818065D0 (en) Immunogenic peptides and uses thereof
IL220146A0 (en) Tmem22 peptides and vaccines including the same
IL215268A0 (en) C6orf167 peptides and vaccines containing the same
ZA201104890B (en) Wdrpuh epitope peptides and vaccines containing the same
IL219927A0 (en) Mybl2 peptides and vaccines containing the same
GB0823492D0 (en) Antigenic peptides and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120131

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/12 20060101ALI20120125BHEP

Ipc: A61K 38/02 20060101ALI20120125BHEP

Ipc: A61K 35/76 20060101AFI20120125BHEP

17Q First examination report despatched

Effective date: 20131016

PUAJ Public notification under rule 129 epc

Free format text: ORIGINAL CODE: 0009425

32PN Public notification

Free format text: INVITATION TO GIVE NOTICE OF APPOINTMENT OF A PROFESSIONAL REPRESENTATIVE (EPO FORM 2502B DATED 02/02/2015)

PUAJ Public notification under rule 129 epc

Free format text: ORIGINAL CODE: 0009425

32PN Public notification

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 2524 DATED 19.04.2016)

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160105